Methodology
What This Page Is
Peptide Breakdown exists to summarize and contextualize scientific evidence on peptides. We do not recommend products, prescribe protocols, or advocate for any particular course of action. The goal is to present what the research says, acknowledge what it does not say, and make the distinction between the two as clear as possible.
This page explains how we evaluate evidence, why we choose specific language, and what standards govern the content on this site.
Evidence Hierarchy
Not all evidence carries the same weight. We evaluate findings based on where they fall in a hierarchy, ordered by reliability and relevance to humans:
- Human clinical trials — Controlled studies in human participants, ideally randomized, blinded, and published in peer-reviewed journals. This is the strongest form of evidence for any claim about how a compound behaves in humans.
- Observational human data — Epidemiological studies, case reports, and retrospective analyses involving human subjects. Useful for identifying patterns, but limited by confounding variables and lack of controlled conditions.
- Animal studies — Research conducted in rodents, primates, or other animal models. These can demonstrate biological plausibility but do not confirm that the same effects occur in humans. Dose scaling, metabolic differences, and species-specific biology all limit direct translation.
- In vitro and mechanistic studies — Cell culture, tissue models, and biochemical analyses. These explain how a compound interacts at the molecular level but say nothing definitive about whole-organism outcomes.
- Theoretical or anecdotal observations — Mechanistic reasoning without direct experimental support, or user-reported experiences without controlled verification. Included for context when relevant, but never treated as evidence of effect.
A finding supported only by animal or in vitro data does not imply effectiveness or safety in humans. We state the evidence tier explicitly so readers can judge the strength of any claim for themselves.
How Confidence Is Expressed
Language on this site is chosen deliberately. When we write "may support," "limited evidence suggests," or "preclinical data indicates," those qualifiers reflect the actual state of the research, not a stylistic preference for hedging.
The principle is straightforward: the language should match the evidence. A compound studied in one small rat trial does not warrant the same confidence as one studied across multiple large human trials. When the data is uncertain, the writing says so. When the data is robust, the writing reflects that too.
Uncertainty is not a weakness of the content. It is an accurate description of where the science stands.
What This Site Does Not Do
To avoid any ambiguity:
- We do not prescribe, recommend, or advise the use of any compound.
- We do not claim that any peptide provides a specific benefit.
- We do not guarantee the safety of any compound, including those with extensive clinical data.
- We do not extrapolate beyond what the available evidence supports. If a study was conducted in mice, we say it was conducted in mice.
Content on this site is informational. It is not a substitute for professional medical guidance.
Preclinical Research Explained
A large proportion of peptide research is preclinical, meaning it has not been tested in human clinical trials. This applies to many of the compounds covered on this site.
Preclinical findings are exploratory. A peptide that shows a measurable effect in cell culture or an animal model has demonstrated biological activity under specific laboratory conditions. That result does not confirm the same effect will occur in a living human body at any dose.
Many compounds with strong preclinical profiles never advance to human trials, or fail when they do. The reasons vary: toxicity at effective doses, poor bioavailability, species-specific mechanisms, or simply lack of funding for further research. A promising mechanism is not a validated outcome.
We cover preclinical compounds because they represent the majority of what exists in the peptide research landscape. Excluding them would leave most of the field unaddressed. But we are explicit about the limitations of the evidence in every case.
How Content Is Updated
Pages on this site are not static. When new research is published, we update the relevant content to reflect it. This includes adjusting confidence language upward when findings are replicated in stronger study designs, and adjusting it downward when contradictory evidence emerges or methodological concerns are identified.
The date at the top of each article reflects when the content was last reviewed or modified. If a page has not been updated recently, it means no significant new evidence has been identified since the last review, not that the page has been neglected.
Who This Site Is For
Peptide Breakdown is written for informed readers who want access to research summaries without marketing bias. This includes people with a general science background, health-conscious individuals evaluating peptide research, and anyone who prefers primary sources over vendor claims.
This site is not designed for people seeking purchase recommendations, dosing protocols, or confirmation that a specific compound will produce a desired effect. If you are looking for someone to tell you what to take or how much, this is not that resource.
Corrections or research feedback: editorial@peptidebreakdown.com